25.40
5.39%
+1.30
(After Hours:
25.45
+0.0500
+0.20%)
Apr-09-21 09:00AM | Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021GlobeNewswire |
Mar-30-21 09:30AM | Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial OfficerPR Newswire |
Mar-24-21 04:10AM | Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business UpdatesGlobeNewswire |
Mar-17-21 09:00AM | FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell TherapiesGlobeNewswire |
Feb-08-21 05:24AM | Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire |
Feb-03-21 11:22AM | Sana Announces Upsized Pricing of Initial Public OfferingGlobeNewswire |
Sana Biotechnology, Inc. develops and delivers engineered cells as medicine for patients. It identifies and develops potential product candidates; and executes preclinical studies. The company develops technologies to repair and control genes in cells; and replace any cell in the body. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was founded in 2018 and is based in Seattle, Washington with additional offices in South San Francisco, California; and Cambridge, Massachusetts.
List of Zack Morris Stocks
List of SPAC Stocks
List of EV Stocks and Related Stocks
Top 100 popular stocks on Robinhood
List of Marijuana Stocks
Cap:
|
Volume (24h):